Amarin Corp. PLC ADR (AMRN) News
Filter AMRN News Items
AMRN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AMRN News Highlights
- For AMRN, its 30 day story count is now at 4.
- Over the past 22 days, the trend for AMRN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC and FOLD are the most mentioned tickers in articles about AMRN.
Latest AMRN News From Around the Web
Below are the latest news stories about AMARIN CORP PLC that investors may wish to consider to help them evaluate AMRN as an investment opportunity.
13 Most Promising Small-Cap Stocks According to AnalystsIn this piece, we will take a look at the 13 most promising small-cap stocks according to analysts. If you want to skip our overview of small cap investing and the latest stock market news, then you can take a look at the 5 Most Promising Small-Cap Stocks To Buy. Within the broader world of […] |
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its participation in the 42nd Annual JP Morgan Healthcare Conference. Amarin’s president and chief executive officer, Patrick Holt, is scheduled to present at the conference on January 10, 2024. 42nd Annual J.P. Morgan Healthcare Conference (January 8th-11th, 2024; San Francisco, California) Date/Time: January 10, 2024, 4:30 p.m. ET/ 1:30 p.m. PST Webcast: https://jpmorga |
Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
What Makes Amarin (AMRN) a New Buy StockAmarin (AMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo -- -- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease -- -- Findings Continue to Reinforce the Scientific Data and Clinical Use of VASCEPA®/VAZKEPA® to Reduce Cardiovascular Risk -- -- Results Presented Today at the American Heart Association (AHA) Scientific Sessions 2023 and Simultaneously Published in the European Heart Journal Open -- DUBLIN, Ireland |
Amarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call TranscriptAmarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript November 1, 2023 Amarin Corporation plc misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.02. Operator: Welcome to Amarin Corporation’s conference call to discuss its third quarter 2023 financial results and business updates. I would now like to turn the conference call over […] |
Are Investors Undervaluing Amarin Corporation plc (NASDAQ:AMRN) By 27%?Key Insights The projected fair value for Amarin is US$0.95 based on 2 Stage Free Cash Flow to Equity Amarin is... |
Amarin Plc (AMRN) Q3 2023 Earnings Call TranscriptWelcome to Amarin Corporation's conference call to discuss its third-quarter 2023 financial results and business updates. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided under Federal Securities law. |
Amarin (AMRN) Q3 Earnings and Revenues Surpass EstimatesAmarin's (AMRN) third-quarter 2023 earnings and revenues beat estimates. Vascepa sales in the United States decline year over year. |
Amarin (AMRN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesWhile the top- and bottom-line numbers for Amarin (AMRN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |